

ARM Foundation for Cell and Gene Medicine Programs



ARM Foundation
for Cell & Gene Medicine

A number one concern of people considering gene medicine is the difficulty of making an informed decision. Patients and caregivers want to be engaged and educated about next generation medicines and are asking for educational resources.



HEALINGGENES.ORG

Healing Genes is an educational initiative from the ARM Foundation that provides comprehensive, easy-to-understand and easy-to-access educational resources about cell and gene medicine.

[HealingGenes.org](https://healinggenes.org) supports the public, patients, caregivers, healthcare providers, and other stakeholders seeking information about cell and gene medicine.

[HealingGenes.org](https://healinggenes.org) has information for news and social media influencers to cover cell and gene medicine.

[HealingGenes.org](https://healinggenes.org) provides accurate, jargon-free information and resources about the science, benefits, limitations, and challenges of therapeutic gene-based medicine.



HEALTH & ECONOMIC IMPACT PROGRAM

The ARM Foundation is conducting in-depth analyses of the system impact of regenerative medicines on national and international healthcare economies.

The result will be advanced pharmacoeconomic simulation models of regenerative medicines in several major disease areas to quantify the value of curative therapies compared to the current standard of care.

“There is now hope for people with complex rare disorders and other intractable diseases because of cell and gene medicine. Cell and gene medicine will undoubtedly result in disease modifying, symptom relieving, and curative therapeutic options.”

– BRETT KOPELAN, CHAIR, ARM FOUNDATION;
EXECUTIVE DIRECTOR, DEBRA OF AMERICA



STATE RARE DISEASE EDUCATION INITIATIVE

STRiDE is a national program to engage and inform key members of the rare disease community at state and local levels about the changing landscape of cell and gene medicine for diagnosis, treatment, and intervention in rare disease.

Availability and access to cell and gene medicines for the national rare disease population depends on strong support from key constituencies at the state and local level.

STRiDE wants to fill a critical education gap at the state level.

Empowered by relevant data and actionable information, families, patient organizations, and key decision-makers can better understand the potential of cell and gene therapies and improve access to innovative therapies.